Neuronetics, Inc., Announces First Patients Enrolled in Clinical Trial to Evaluate NeuroStar TMS Therapy in Women with Postpartum Depression
Open-label Study will Assess the Safety and Efficacy of NeuroStar Transcranial Magnetic Stimulation (TMS) among Postpartum Patients through One Year MALVERN, Pa., July 30, 2013 – Neuronetics, Inc., the maker of a non-drug depression treatment, announced today the enrollment of the first five patients in an open-label clinical trial to evaluate NeuroStar TMS Therapy® System [...]
MOUNTAIN VIEW, CA, July 16, 2013 –Adaptive Planning, the worldwide leader in cloud-based business analytics solutions for companies and nonprofits of all sizes, today announced that it has been chosen by AlwaysOn as one of the AlwaysOn Global 250 winners.
Valeritas announces new findings from observational study suggesting that delivery of insulin via V-GO® may improve glycemic control and reduce total daily insulin dose for patients with type 2 diabetes
CHICAGO and BRIDGEWATER, N.J., June 22, 2013 — Valeritas, makers of the V-Go® insulin delivery device, today announced new findings from a planned interim analysis of data from the SIMPLE study that suggests that patients with Type 2 diabetes who switched to the V-Go insulin delivery device from their previous baseline treatment experienced improved glycemic [...]
ALISO VIEJO, Calif., June 19, 2013 – Vertos Medical Inc., which has pioneered the mild® procedure — a safe, outpatient procedure that can help patients diagnosed with lumbar spinal stenosis (LSS) stand longer and walk farther with less pain1 – announced today that it has closed nearly $23 million in financing.
Valeritas Expanding V-Go US Commercial Operations BRIDGEWATER, N.J., June 4, 2013 – Valeritas, makers of the V-Go® insulin delivery device, today announced that they have closed a structured debt financing with Capital Royalty L.P. which provides Valeritas with up to $100 million to further support the commercialization of the V-Go. “We are pleased to have [...]
New Data Show Long - Term Benefit of Transcranial Magnetic Stimulation in Difficult - to - Treat Patients with Depression using NeuroStar TMS Therapy System
Largest clinical study evaluating durability of Transcranial Magnetic Stimulation (TMS) shows depression patients maintained remission through 52 weeks with the NeuroStar SAN FRANCISCO, May 21, 2013 – New data released today at the annual meeting of the American Psychiatric Association show that the NeuroStar TMS Therapy System ® induced statistically and clinically meaningful response and [...]
Mountain View, Calif., May 21, 2013 – Adaptive Planning, the worldwide leader in cloud-based business analytics solutions for companies and nonprofits of all sizes, today announced at its Accelerate 2013 global user conference that it has secured a major new round of $45 million in venture funding.
LONDON, April 24, 2013 /PRNewswire/ — Adara, the global leader in data-driven marketing, today announced an exclusive partnership with Ryanair, Europe’s only ultra-low cost carrier (ULCC).